Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Winner
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
.
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Questcor Pharmaceuticals rose 34 cents (1.3%) to $25.70 on light volume. Throughout the day, 1.7 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 5.6 million shares. The stock ranged in a price between $24.83-$25.86 after having opened the day at $25.65 as compared to the previous trading day's close of $25.36. Other companies within the Drugs industry that increased today were:
(
), up 21.4%,
(
), up 20.9%,
Catalyst Pharmaceutical Partners
(
), up 17%, and
Dynavax Technologies Corporation
(
), up 13.4%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.46 billion and is part of the health care sector. The company has a P/E ratio of 9.6, below the S&P 500 P/E ratio of 17.7. Shares are down 39.8% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.
TheStreet Ratings rates Questcor Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.
- You can view the full Questcor Ratings Report.
On the negative front,
(
), down 12.3%,
(
), down 10.7%,
Nymox Pharmaceutical Corporation
(
), down 10.4%, and
(
), down 10.2%, were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!
.
null